CIK 0001649094 · Large accelerated filer
Vaxcyte, Inc.
Sign in to watch- Ticker
- PCVX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464233385
- Phone
- 650-837-0111
- Business address
- 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070
- Former names
- SutroVax, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,032,885
- in 7 filings, $3.7M under 10b5-1 plans
Net −$4,032,885. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-27 | PICKERING GRANT CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (right to buy) | +193,431 | 193,431 | ||
| 2025-02-18 | GUGGENHIME ANDREW PRESIDENT AND CFO | Option exercise 10b5-1 | +8,000 | $5.35 | $43K | 117,491 |
| 2025-02-18 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 | −6,182 | $83.64 | $517K | 111,309 |
| 2025-02-18 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 | −1,818 | $84.58 | $154K | 109,491 |
| 2025-02-18 | GUGGENHIME ANDREW PRESIDENT AND CFO | Option exercise · Stock Option (right to buy) 10b5-1 | −8,000 | 246,827 | ||
| 2025-02-05 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Option exercise 10b5-1 | +5,000 | $21.41 | $107K | 33,222 |
| 2025-02-05 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Sale 10b5-1 | −571 | $87.77 | $50K | 32,651 |
| 2025-02-05 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Sale 10b5-1 | −635 | $89.09 | $57K | 32,016 |
| 2025-02-05 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Sale 10b5-1 | −1,755 | $89.95 | $158K | 30,261 |
| 2025-02-05 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Sale 10b5-1 | −1,784 | $91.05 | $162K | 28,477 |
| 2025-02-05 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Sale 10b5-1 | −255 | $91.71 | $23K | 28,222 |
| 2025-02-05 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 149,497 | ||
| 2025-02-03 | Wassil Jim CHIEF OPERATING OFFICER | Option exercise 10b5-1 | +8,000 | $2.42 | $19K | 213,695 |
| 2025-02-03 | Wassil Jim CHIEF OPERATING OFFICER | Sale 10b5-1 | −5,314 | $86.00 | $457K | 208,381 |
| 2025-02-03 | Wassil Jim CHIEF OPERATING OFFICER | Sale 10b5-1 | −2,666 | $86.67 | $231K | 205,715 |
| 2025-02-03 | Wassil Jim CHIEF OPERATING OFFICER | Sale 10b5-1 | −20 | $87.94 | $2K | 205,695 |
| 2025-02-03 | Wassil Jim CHIEF OPERATING OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −8,000 | 2,638 | ||
| 2025-01-21 | GUGGENHIME ANDREW PRESIDENT AND CFO | Option exercise 10b5-1 | +8,000 | $5.35 | $43K | 117,491 |
| 2025-01-21 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 | −5,318 | $86.08 | $458K | 112,173 |
| 2025-01-21 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 | −1,999 | $87.25 | $174K | 110,174 |
Page 13 of 16 · 319 trades